Provectus Biopharmaceuticals, Inc. (PVCT)
Stock Price:
$0.0899 USD
-0.0039 (-4.16%)
Updated Aug 13, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
35.12M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-6.82M |
| Shares Out |
390.69M |
| EPS (ttm) |
-0.02 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 13, 2020 |
| Last Price |
$0.0899 |
| Previous Close |
$0.0938 |
| Change ($) |
-0.0039 |
| Change (%) |
-4.16% |
| Day's Open |
0.0919 |
| Day's Range |
0.0880 - 0.0937 |
| Day's Volume |
239,083 |
| 52-Week Range |
0.0300 - 0.1300 |
More Stats
| Market Cap |
35.12M |
| Enterprise Value |
56.51M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
390.69M |
| Float |
373.50M |
| EPS (basic) |
-0.01 |
| EPS (diluted) |
-0.02 |
| FCF / Share |
-0.01 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.82M |
| Short Ratio |
0.47 |
| Short % of Float |
0.78% |
| Beta |
0.60 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
5.44 |
| Revenue |
n/a |
| Operating Income |
-5.32M |
| Net Income |
-6.82M |
| Free Cash Flow |
-4.32M |
| Net Cash |
-21.39M |
| Net Cash / Share |
-0.05 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-162.75% |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
3.50
Current: $0.0899
High
3.50
Target: 3.50
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -6.30 | -8.05 | -13.32 | -24.95 | -24.65 | -16.81 | -13.03 | -14.34 | -21.44 | -20.69 |
| Net Income | -6.92 | -8.15 | -13.52 | -24.43 | -24.50 | -10.24 | -27.70 | -12.57 | -19.43 | -18.55 |
| Shares Outstanding | 387 | 382 | 369 | 234 | 196 | 176 | 132 | 113 | 106 | 78.82 |
| Earnings Per Share | -0.02 | -0.02 | -0.04 | -0.12 | -0.13 | -0.06 | -0.22 | -0.11 | -0.19 | -0.37 |
| Operating Cash Flow | -6.19 | -5.20 | -10.35 | -21.94 | -17.41 | -13.85 | -9.89 | -11.26 | -17.20 | -13.73 |
| Capital Expenditures | - | - | -0.03 | - | -0.01 | -0.07 | -0.01 | -0.02 | -0.01 | - |
| Free Cash Flow | -6.19 | -5.20 | -10.38 | -21.94 | -17.42 | -13.92 | -9.90 | -11.27 | -17.21 | -13.73 |
| Cash & Equivalents | 0.59 | 0.05 | 0.11 | 1.17 | 14.18 | 17.39 | 15.70 | 1.22 | 7.71 | 8.09 |
| Total Debt | 20.37 | 13.93 | 9.46 | - | - | - | - | - | - | - |
| Net Cash / Debt | -19.78 | -13.88 | -9.35 | 1.17 | 14.18 | 17.39 | 15.70 | 1.22 | 7.71 | 8.09 |
| Assets | 1.48 | 1.99 | 3.44 | 5.61 | 20.44 | 26.18 | 20.01 | 6.20 | 13.35 | 14.40 |
| Liabilities | 25.55 | 19.41 | 13.46 | 2.14 | 4.12 | 0.99 | 13.38 | 1.81 | 3.33 | 3.70 |
| Book Value | -24.07 | -17.42 | -10.02 | 3.47 | 16.32 | 25.19 | 6.63 | 4.39 | 10.02 | 10.70 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Provectus Biopharmaceuticals, Inc. |
| Country |
United States |
| Employees |
2 |
| CEO |
Bruce Horowitz |
Stock Information
| Ticker Symbol |
PVCT |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: PVCT |
Description
Provectus Biopharmaceuticals, Inc., a biopharmaceutical company, engages in developing drugs based on halogenated xanthenes for oncology and dermatology indications. Its prescription drug candidates include PV-10, which is in Phase III study for cutaneous melanoma; completed Phase II study for metastatic melanoma; completed Phase I study for liver and breast cancers; and phase 1b/2 study for pembrolizumab. The company is also developing PH-10 that has completed Phase II randomized study for the treatment of psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.